SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is experiencing heightened volatility as market participants react to recent geopolitical rhetoric from former President Trump, particularly concerning potential tariffs and comments about Greenland, which has sparked significant uncertainty among international allies. Community sentiment reflects apprehension about these developments, fueling discussions around a potential "Sell America" trade and a noticeable shift toward safe-haven assets like gold and silver amid broader economic and geopolitical concerns.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. is trending amid its announced record date for a new digital token initiative, which the community is discussing as a potential catalyst for a short squeeze. This development, coupled with ongoing geopolitical narratives and commentary surrounding its figurehead, fuels significant market speculation and contributes to its high volatility.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is highly active amidst intense discussions fueled by geopolitical developments, specifically related to rhetoric from Davos concerning Greenland and potential tariffs impacting European allies. Community sentiment is bifurcated, with many anticipating continued declines from global instability and upcoming interest rate decisions, while a significant portion of traders are actively buying the dip, expecting a customary market rebound despite the contentious headlines.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending following a key licensing agreement with Pfizer for its Matrix-M adjuvant technology, which the community views as a significant validation for the platform and a catalyst for potential future collaborations. Many are actively discussing the stock's high short interest, anticipating a substantial market move as the short thesis weakens. Despite this positive development, debates continue around management's overall strategy to maximize shareholder value and secure additional deals for its pipeline assets.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending dramatically after announcing promising Phase 1 clinical trial results for its oral drug, soquelitinib, treating moderate to severe atopic dermatitis with strong efficacy and a favorable safety profile. The market is actively discussing the drug's potential, especially for patients resistant to current therapies, driving speculation of significant upside and a short squeeze, though some caution against the early trial stage and potential dilution.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is a focal point of market discussion after recently upgrading its bid for Warner Bros. Discovery assets to an all-cash offer, a strategic move generating debate about its long-term growth prospects ahead of the upcoming earnings report. Community sentiment is sharply divided, with many seeing the stock as oversold and ripe for a rebound, while others express caution regarding the deal's implications and broader market headwinds.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple (AAPL) is currently experiencing highly polarized community sentiment, with many expressing frustration over its recent price decline, perceived lack of AI innovation, and broader market weakness. However, a strong counter-narrative highlights the stock as deeply oversold with historically low RSI levels, presenting a significant "buy the dip" opportunity ahead of its anticipated strong holiday quarter earnings. Geopolitical tensions and ongoing tariff discussions are further fueling volatility and shaping investor outlook on the tech giant.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following positive regulatory developments, as the FDA requested no new trials for its ANKTIVA cancer therapy's sBLA resubmission, signaling an accelerated path to market. The community is buzzing with optimism, anticipating substantial long-term growth driven by this key de-risking event and international market opportunities, while also discussing the potential for a significant short squeeze.

ProShares Trust - ProShares Ultra VIX Short-Term Futures ETF 1.5x Shares

ProShares Ultra VIX Short-Term Futures ETF

UVXY is trending amid intensified geopolitical rhetoric and upcoming central bank decisions, driving speculation for a potential surge in market volatility. While some traders anticipate significant upward movement, the community largely discusses its inherent decay, making it a popular instrument for short-selling and a challenging long-term hold. This highlights the ongoing tug-of-war between event-driven fear and the structural nature of volatility products.

ProShares Trust - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is trending after natural gas prices surged dramatically, driven by renewed forecasts for colder weather and increased heating demand. This has led to a steep decline in the inverse ETF, shocking many traders who are now debating whether KOLD presents a "buy the dip" opportunity or if further downside is imminent. The extreme volatility underscores the speculative nature of natural gas leveraged products, with the community sharply divided on KOLD's immediate future.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Akebia Therapeutics (NASDAQ:AKBA) Shares Cross Below Fifty Day Moving Average - Here's Why

Akebia Therapeutics (NASDAQ:AKBA) Stock Crosses Below Fifty Day Moving Average - Here's Why...

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the eight brokerages that are currently covering the company...

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eight research firms that are presently covering the company...

<ul class="summary-bullets"><li>ADX-097 is designed to inhibit complement activation, an integral part of the innate immune system, and has potential across kidney, autoimmune, vascular and skin diseases.</li><li>Q32 Bio is also eligible to receive tiered royalties on potential future sales of ADX-097, ranging from low single-digit to mid-teen percentages.</li><li>The company is now focussed on advancing Bempikibart for patients with alopecia areata.</li></ul> Shares of Q32 Bio Inc. (QTTB) jumped 98% on Monday after the company sold its experimental drug ADX-097, to Akebia Therapeutics, Inc. (AKBA) for up to $592 million.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.q32bio.com/news-releases/news-release-details/q32-bio-sells-complement-inhibitor-adx-097">said</a> that the sale extends its cash runway into the second half of 2027. ADX-097 is designed to inhibit complement activation, an integral part of the innate immune system, and has potential across kidney, autoimmune, vascular and skin diseases.<h2 class="st-heading-2">Terms Of The Deal</h2>Akebia will now be responsible for future development and commercialization of ADX-097. Under the deal, Q32 Bio will receive $12 million in upfront payments and near-term milestone payments.These payments as well as potential development, regulatory and commercial milestones total up to $592 million, the company said. Q32 Bio is also eligible to receive tiered royalties on potential future sales of ADX-097, ranging from low single-digit to mid-teen percentages.ADX-097 is the lead product candidate from Q32 Bio's tissue-targeted complement inhibitor platform. Q32 Bio, however, retains the rights to the platform, including ADX-096 being developed for ophthalmologic indications and other remaining early-stage assets and is continuing to evaluate strategic options for these programs.The company is now focussed on advancing Bempikibart for patients with alopecia areata, an autoimmune disorder that causes the immune system to attack hair follicles, resulting in sudden, patchy hair loss, most commonly on the scalp.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/QTTB">QTTB stock</a> stayed within the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.<figure class="image"><img style="aspect-ratio:586/57;" src="data:image/png;base64,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" alt="QTTB’s Sentiment Meter and Message Volume as of 12:40 p.m. ET on Nov. 28, 2025 | Source: Stocktwits" width="586" height="57"><figcaption>QTTB’s Sentiment Meter and Message Volume as of 12:40 p.m. ET on Dec. 1, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user sees the deal opening opportunities for the company.<stembedurl>https://stocktwits.com/topstockalerts/message/637812919</stembedurl>QTTB stock is up by 26% this year but down by about 84% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/connecticut-attorney-general-presses-bnpl-firms-paypal-sezzle-on-fees-disclosure-debt-risks/cLI71TxREiD">Connecticut Attorney General Presses BNPL Firms PayPal, Sezzle On Fees, Disclosures And Debt Risks</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Q32 Bio Stock Soars On Selling Experimental Drug To Akeba For Up To $592M

The company said that the sale extends its cash runway into the second half of 2027.

Equity

The company said that the sale extends its cash runway into the second half of 2027.


Q32 Bio Sells Complement Inhibitor ADX-097

Q32 Bio Sells Complement Inhibitor ADX-097 Q32 Bio Sells Complement Inhibitor ADX-097 PR Newswire WALTHAM, Mass., Dec. 1, 2025 -- Asset sale further enables Company's strategic focus on advancing...

Akebia Therapeutics (NASDAQ:AKBA) Downgraded by Wall Street Zen to "Buy"

Wall Street Zen lowered Akebia Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday...

Q2 Earnings Forecast for AKBA Issued By HC Wainwright

Akebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) - Equities researchers at HC Wainwright issued their Q2 2026 EPS estimates for shares of Akebia Therapeutics in a research note issued to...

Implied Volatility Surging for Akebia Therapeutics Stock Options

Investors need to pay close attention to AKBA stock based on the movements in the options market lately.

Analysts Offer Predictions for AKBA Q1 Earnings

Akebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Akebia Therapeutics in a research note issued...

Theravance's Q3 Earnings Surpass Estimates, Revenues Match

TBPH delivers a third-quarter profit, beating estimates, and 19% revenue growth, fueled by rising collaboration income from Viatris related to Yupelri sales.

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vafseo. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Akebia Therapeutics Inc.

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

Current Price	$1.34
Prev Close	$1.36
Open	$1.32
Dividend Yield	0.00%
50-Day Moving Average	$1.62
Beta	1.46
Avg. Volume	3.1M
PE Ratio	-17.87

52-Week High	$4.08
52-Week Low	$1.31
Market Capitalization	$360.9M
EPS (Annual)	-$0.329
Price to Book	8.67
Revenue Per Employee	$884,972.38
Enterprise Value/EBITDA	N/A

AKBA
Akebia Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AKBA News

AKBAAkebia Therapeutics Inc.